Ron Bentsur Insider Trades & Stock Holdings

Chairman & CEO · Nuvectis Pharma, Inc. · Latest filing Jun 30, 2026

Ron Bentsur, Chairman & CEO at Nuvectis Pharma, Inc. has 1 Form 4 trade on file since Jun 30, 2026. Open-market activity: 1 purchase ($250K) and 0 sales ($0), net +$250K. Latest filing: acquired 12.50K shares of $NVCT on Jun 30, 2026 at $20.

Trades on file

1

Open-market bought

$250K

Open-market sold

$0

Net open-market

+$250K

Latest filing

Jun 30, 2026

All insider trades by Ron Bentsur

Date	Ticker	Type	Shares	Price	Value	Owned after	ΔOwn	1W	1M	6M	Role	Filing	Story
Jun 30, 2026	$NVCT	Buy (Open-market buy)	12.50K	$20	$250K			+4.4%	+23.8%		Chairman & CEO		Read

"Buy" means shares acquired on the Form 4 (including grants and option exercises); "Sell" means shares disposed. 1W / 1M / 6M = how the stock moved after the trade.

Stocks Ron Bentsur traded

• $NVCT

Frequently asked questions

Has Ron Bentsur been buying or selling stock?

Ron Bentsur has 1 open-market purchase and 0 open-market sales on file, net +$250K. Grants, option exercises and tax withholding are listed separately because they are not open-market trades.

What was Ron Bentsur's latest insider trade?

acquired 12.50K shares of $NVCT on Jun 30, 2026 at $20.

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.